Stanley F Barnett

Author PubWeight™ 18.68^‹?›

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors.	Bioorg Med Chem Lett	2005	3.50
2	Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members.	Mol Cancer Ther	2005	2.23
3	Allosteric inhibitors of Akt1 and Akt2: a naphthyridinone with efficacy in an A2780 tumor xenograft model.	Bioorg Med Chem Lett	2008	1.44
4	The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors.	Curr Cancer Drug Targets	2008	1.40
5	Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors.	Bioorg Med Chem Lett	2005	1.27
6	Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors.	Curr Top Med Chem	2007	1.06
7	Effective siRNA delivery and target mRNA degradation using an amphipathic peptide to facilitate pH-dependent endosomal escape.	Biochem J	2011	1.05
8	Quantitative evaluation of siRNA delivery in vivo.	RNA	2010	1.03
9	Development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved physical properties and cell activity.	Bioorg Med Chem Lett	2007	0.98
10	Allosteric inhibitors of Akt1 and Akt2: discovery of [1,2,4]triazolo[3,4-f][1,6]naphthyridines with potent and balanced activity.	Bioorg Med Chem Lett	2008	0.86
11	Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors.	Bioorg Med Chem Lett	2007	0.86
12	Discovery of potent and cell-active allosteric dual Akt 1 and 2 inhibitors.	Bioorg Med Chem Lett	2008	0.81
13	Rapid assembly of diverse and potent allosteric Akt inhibitors.	Bioorg Med Chem Lett	2007	0.80
14	Development of pyridopyrimidines as potent Akt1/2 inhibitors.	Bioorg Med Chem Lett	2008	0.79
15	The design and synthesis of potent and cell-active allosteric dual Akt 1 and 2 inhibitors devoid of hERG activity.	Bioorg Med Chem Lett	2008	0.79